Paul McKenzie - CSL Chief Officer
| CSLLY Stock | USD 91.13 0.41 0.45% |
Executive
Dr. Paul F. McKenzie is appointed as Chief Operating Officer of the Company., effective 3 June 2019. He has served in a range of progressive operational leadership roles in the biopharma and biotech industries since 1992. Most recently, he was Executive Vice President of Pharmaceutical Operations Technology at Biogen where he was accountable for asset management, technical development, global manufacturing, supply chain operations, CMC regulatory, quality and engineering. Dr. McKenzie also held leadership roles in research development, science technology and operations with Johnson Johnson, BristolMyers Squibb and Merck earlier in his career. He earned his BS degree in Chemical Engineering from the University of Pennsylvania and was awarded his Ph.D. in Chemical Engineering from Carnegie Mellon University. Dr. McKenzie is an accomplished author and thought leader on operational excellence in the biotech industry. since 2019.
| Age | 57 |
| Tenure | 5 years |
| Phone | 61 3 9389 1911 |
| Web | https://www.csl.com.au |
CSL Management Efficiency
The company has return on total asset (ROA) of 0.0613 % which means that it generated a profit of $0.0613 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1338 %, meaning that it generated $0.1338 on every $100 dollars invested by stockholders. CSL's management efficiency ratios could be used to measure how well CSL manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MD MBA | Molecular Partners AG | N/A | |
| David Wustrow | RAPT Therapeutics | 65 | |
| Sheila MD | Ventyx Biosciences | 54 | |
| Michelle MD | PepGen | 48 | |
| Renate Gloggner | Molecular Partners AG | 54 | |
| Shephard MD | ACELYRIN, INC Common | N/A | |
| Tyler Marciniak | ACELYRIN, INC Common | N/A | |
| Mollie MD | Kura Oncology | N/A | |
| Brad Fell | Cogent Biosciences | N/A | |
| Dana PharmD | Cogent Biosciences | N/A | |
| Minji MBA | Mineralys Therapeutics, Common | N/A | |
| Patricia Turney | ACELYRIN, INC Common | 57 | |
| Steve Young | RAPT Therapeutics | N/A | |
| Jan Smith | Revolution Medicines | N/A | |
| Steven Closter | Syndax Pharmaceuticals | N/A | |
| David MD | Mineralys Therapeutics, Common | 69 | |
| Stefan Abele | Pharvaris BV | 54 | |
| Perrin BS | Nuvalent | N/A | |
| John Paolini | Kiniksa Pharmaceuticals | 59 | |
| JD Esq | Kura Oncology | 53 | |
| Steve Sabus | Syndax Pharmaceuticals | 57 | |
Management Performance
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0613 |
CSL Leadership Team
Elected by the shareholders, the CSL's board of directors comprises two types of representatives: CSL inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CSL. The board's role is to monitor CSL's management team and ensure that shareholders' interests are well served. CSL's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CSL's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Paul McKenzie, Chief Officer | ||
| BCom BComm, Chief Officer | ||
| Wilfried Freudenberg, Department Production | ||
| Christina Hickie, Sr Communications | ||
| BS BS, Exec Counsel | ||
| MS BA, Ex Officer | ||
| Karen Etchberger, Executive VP of Quality and Bus. Services | ||
| Paul BA, CEO MD | ||
| Jemimah Brennan, Head Pacific | ||
| Mark Dehring, Head of Investor Relations |
CSL Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is CSL a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0613 | |||
| Profit Margin | 0.18 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 96.65 B | |||
| Shares Outstanding | 964.43 M | |||
| Shares Owned By Institutions | 0.07 % | |||
| Price To Earning | 34.45 X | |||
| Price To Book | 6.77 X | |||
| Price To Sales | 9.04 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CSL Pink Sheet Analysis
When running CSL's price analysis, check to measure CSL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CSL is operating at the current time. Most of CSL's value examination focuses on studying past and present price action to predict the probability of CSL's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CSL's price. Additionally, you may evaluate how the addition of CSL to your portfolios can decrease your overall portfolio volatility.